SCHEDULE 13G/A: Janus Henderson Group Discloses 7.2% Stake in Ascendis Pharma A/S

Janus Henderson Group plc has filed an Amendment No. 5 to its Schedule 13G, reporting a beneficial ownership of 7.2% in Ascendis Pharma A/S as of December 31, 2024.

Summary

• Janus Henderson Group plc, a Jersey-based parent holding company and investment adviser, has filed an Amendment No. 5 to its Schedule 13G regarding its beneficial ownership in Ascendis Pharma A/S.
• As of December 31, 2024, Janus Henderson Group plc beneficially owns 4,380,382 American Depositary Shares of Ascendis Pharma A/S.
• This ownership represents 7.2% of the total class of securities.
• The shares are held with shared voting power and shared dispositive power, with no sole voting or dispositive power.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Ascendis Pharma A/S.
• Indirect subsidiaries, JHIUS, JHIUKL, and JHIAIFML, are identified as registered investment advisers furnishing investment advice to Managed Portfolios.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing (Schedule 13G) reporting beneficial ownership. It is factual and contains no subjective language or forward-looking statements that would indicate positive or negative sentiment regarding the issuer's performance or outlook.

Positives

• NA

Negatives

• NA

Risks

• NA

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, confirming that Janus Henderson Group plc holds a substantial stake (7.2%) but not for control purposes.
• Regulatory Authorities: Fulfills SEC disclosure requirements for beneficial ownership exceeding 5%.

Key Dates

Keywords

Ascendis Pharma A/S, Janus Henderson Group plc, Schedule 13G, Beneficial Ownership, American Depositary Shares, Institutional Investor, SEC Filing, Investment Adviser